Fulcrum Therapeutics (FULC) Current Assets: 2019-2025
Historic Current Assets for Fulcrum Therapeutics (FULC) over the last 7 years, with Sep 2025 value amounting to $205.9 million.
- Fulcrum Therapeutics' Current Assets fell 23.04% to $205.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $205.9 million, marking a year-over-year decrease of 23.04%. This contributed to the annual value of $249.9 million for FY2024, which is 3.19% up from last year.
- Latest data reveals that Fulcrum Therapeutics reported Current Assets of $205.9 million as of Q3 2025, which was down 6.16% from $219.4 million recorded in Q2 2025.
- In the past 5 years, Fulcrum Therapeutics' Current Assets registered a high of $302.8 million during Q1 2023, and its lowest value of $128.5 million during Q2 2021.
- Over the past 3 years, Fulcrum Therapeutics' median Current Assets value was $249.9 million (recorded in 2024), while the average stood at $251.3 million.
- As far as peak fluctuations go, Fulcrum Therapeutics' Current Assets spiked by 89.10% in 2021, and later declined by 28.03% in 2024.
- Over the past 5 years, Fulcrum Therapeutics' Current Assets (Quarterly) stood at $226.0 million in 2021, then declined by 8.18% to $207.5 million in 2022, then grew by 16.71% to $242.2 million in 2023, then grew by 3.19% to $249.9 million in 2024, then decreased by 23.04% to $205.9 million in 2025.
- Its last three reported values are $205.9 million in Q3 2025, $219.4 million for Q2 2025, and $232.6 million during Q1 2025.